CORTI, FRANCESCA
CORTI, FRANCESCA
Universita' degli Studi di MILANO
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
2022 R. Moretto, A. Elliott, D. Rossini, R. Intini, V. Conca, F. Pietrantonio, A. Sartore-Bianchi, C. Antoniotti, C. Rasola, M. Scartozzi, M. Salati, N. Pella, M.A. Calegari, M. Carullo, F. Corti, G. Mauri, M. Fassan, G. Masi, P. Brodskiy, H. Lenz, A. Shields, S. Lonardi, M. Korn, C. Cremolini
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
2022 M. Niger, F. Nichetti, A. Casadei-Gardini, F. Morano, C. Pircher, E. Tamborini, F. Perrone, M. Canale, D.B. Lipka, A. Vingiani, L. Agnelli, A. Dobberkau, J. Hüllein, F. Korell, C.E. Heilig, S. Pusceddu, F. Corti, M. Droz, P. Ulivi, M. Prisciandaro, M. Antista, M. Bini, L. Cattaneo, M. Milione, H. Glimm, B.C. Köhler, G. Pruneri, D. Hübschmann, S. Fröhling, V. Mazzaferro, F. Pietrantonio, M. Di Bartolomeo, F. de Braud
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
2021 F. Pietrantonio, S. Lonardi, F. Corti, G. Infante, M.E. Elez, M. Fakih, P. Jayachandran, A.T. Shah, M. Salati, E. Fenocchio, L. Salvatore, G. Curigliano, C. Cremolini, M. Ambrosini, J. Ros, R. Intini, F. Nappo, S. Damian, F. Morano, G. Fucà, M. Overman, R. Miceli
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
2021 G. Fucà, F. Corti, M. Ambrosini, R. Intini, M. Salati, E. Fenocchio, P. Manca, C. Manai, F. Daniel, A. Raimondi, F. Morano, S. Corallo, M. Prisciandaro, A. Spallanzani, V. Quarà, C. Belli, M. Vaiani, G. Curigliano, C. Cremolini, F. De Braud, M. Di Bartolomeo, V. Zagonel, S. Lonardi, F. Pietrantonio
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
2021 F. Corti, S. Lonardi, R. Intini, M. Salati, E. Fenocchio, C. Belli, B. Borelli, M. Brambilla, A.A. Prete, V. Quarà, M. Antista, M. Fassan, F. Morano, A. Spallanzani, M. Ambrosini, G. Curigliano, F. de Braud, V. Zagonel, G. Fucà, F. Pietrantonio
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak : COVID-19-adapted Recommendations of the National Cancer Institute of Milan
2020 F. Pietrantonio, F. Morano, M. Niger, S. Corallo, M. Antista, A. Raimondi, M. Prisciandaro, F. Pagani, N. Prinzi, F. Nichetti, G. Randon, M. Torchio, F. Corti, M. Ambrosini, F. Palermo, M. Palazzo, L. Biamonte, M. Platania, C. Sposito, M. Cosimelli, V. Mazzaferro, S. Pusceddu, C. Cremolini, F. de Braud, M. Di Bartolomeo
Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial
2020 F. Pietrantonio, G. Fucà, P. Manca, F. Pagani, A. Raimondi, M. Prisciandaro, G. Randon, F. Corti, F. de Braud, C. Cremolini, R. Miceli
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
2020 F. Pietrantonio, F. Loupakis, G. Randon, A. Raimondi, M. Salati, D. Trapani, F. Pagani, I. Depetris, G. Maddalena, F. Morano, S. Corallo, M. Prisciandaro, F. Corti, V. Guarini, A. Bocconi, A. Marra, C. Belli, A. Spallanzani, M. Fassan, S. Lonardi, G. Curigliano, G. Fucà, M. Di Bartolomeo, F. de Braud
Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis
2019 G. Galli, S. Cavalieri, L. Di Guardo, C. Cimminiello, F. Nichetti, F. Corti, M. Garcia, B. Pappalardi, C. Fallai, F. de Braud, M. Platania, M. Del Vecchio
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
2019 S. Pusceddu, M. Ghidini, M. Torchio, F. Corti, G. Tomasello, M. Niger, N. Prinzi, F. Nichetti, A. Coinu, M. Di Bartolomeo, M. Cabiddu, R. Passalacqua, F. de Braud, F. Petrelli
Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
2019 F. Corti, F. Nichetti, A. Raimondi, M. Niger, N. Prinzi, M. Torchio, E. Tamborini, F. Perrone, G. Pruneri, M. Di Bartolomeo, F. de Braud, S. Pusceddu
“Systemic strategy at the patient’s service”: A congress report on supportive care in oncology
2017 F. Nichetti, R. Lobefaro, F. Pagani, G. Randon, F. Corti, F.G.M. DE BRAUD, L. Celio, M. Platania
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors
2017 S. Pusceddu, N. Prinzi, G. Lo Russo, D. Femia, M. Milione, F. Perrone, E. Tamborini, L. Concas, I. Pulice, C. Vernieri, F. Corti, R. Buzzoni, F. De Braud